Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: Important considerations in the WHO 2020 roadmap and london declaration on neglected tropical diseases

AIDS

Volumn 27, Issue 5, 2013, Pages 675-686

  Seden, Kay ^a   Khoo, Saye ^a   Back, David ^a   Prevatt, Natalie ^b   Lamorde, Mohammed ^c,d   Byakika Kibwika, Pauline ^c,d   Mayito, Jonathan ^c   Ryan, Mairin ^d   Merry, Concepta ^c,d,e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b London Deanery   (United Kingdom)

^c MAKERERE UNIVERSITY   (Uganda)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug interactions; HIV AIDS; Neglected tropical diseases; Pharmacokinetics

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; BENZNIDAZOLE; CLOFAZIMINE; DAPSONE; DIETHYLCARBAMAZINE; EFAVIRENZ; EFLORNITHINE; ETRAVIRINE; IVERMECTIN; MEBENDAZOLE; MEGLUMINE ANTIMONATE; MELARSOPROL; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; PRAZIQUANTEL; PYRANTEL; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; SODIUM STIBOGLUTONATE; STREPTOMYCIN; SURAMIN; TRICLABENDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

AFRICAN TRYPANOSOMIASIS; ASCARIASIS; ASCARIS; BURULI ULCER; CHAGAS DISEASE; CYSTICERCOSIS; DENGUE; DISEASES; DRACUNCULIASIS; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ECHINOCOCCOSIS; HEALTH CARE POLICY; HELMINTHIASIS; HOOKWORM INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; LEPROSY; LYMPHATIC FILARIASIS; NEGLECTED TROPICAL DISEASE; NONHUMAN; PARAGONIMIASIS; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; SCHISTOSOMIASIS; TRACHOMA; TRICHURIASIS; TRICHURIS; TROPICAL DISEASE; TRYPANOSOMIASIS; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; NEGLECTED DISEASES; TROPICAL MEDICINE; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84876396409     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ca9b4     Document Type: Review

References (58)

1. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006; 3:e102.
2. Centers for Disease Control and Prevention, Neglected Tropical Diseases Information URL: http://www.cdc.gov/globalhealth/ntd/[Accessed 28 August 2012].
3. Rawden HC, Kokwaro GO, Ward SA, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 2000; 49:313-322.
4. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise antiparasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003; 59:429-442.
5. Sharland M, editor. Manual of childhood infections; The blue book. 3rd ed. Oxford, UK: Oxford University Press; 2011.
6. Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schläpfer E, et al. Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection 2004; 32:299-302.
7. Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, et al. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol 2009; 65:999-1006.
8. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit 2002; 24:338-345.
9. Egaten® (Triclabendazole) Summary of Product Charateristics, Novartis Pharma AG Basel, Switzerland, Produced 27/7/2000, [Accessed 3 September 2012].
10. Martindale Complete Drug Reference. Pharmaceutical Press, London. URL: www.medicinescomplete.com [Accessed 22 August 2012].
11. Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979; 29:1611-1614.
12. Walton MI, Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 1987; 36:887-896.
13. Lee FY, Workman P, Cheeseman KH. Misonidazole and benznidazole inhibit hydroxylation of CCNU by mouse liver microsomal cytochrome P-450 in vitro. Biochem Pharmacol 1987; 36:1349-1355.
14. de Toranzo EG, Herrera DM, Castro JA. Rat liver nuclear nifurtimox nitroreductase activity. Res Commun Mol Pathol Pharmacol 1997; 98:249-254.
15. Montalto de Mecca M, Diaz EG, Castro JA. Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Toxicol Lett 2002; 136:1-8.
16. Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet 1989; 16:74-85.
17. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004; 84:365-373.
18. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 1981; 30:210-217.
19. Stromectol® (Ivermectin) US Prescribing Information, Merck Sharp & Dohme BV Issued May 2010, [Accessed 4 October 2011].
20. Bronner U, Brun R, Doua F, Ericsson O, Burri C, Keiser J, et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health 1998; 3:913-917.
21. Keiser J, Ericsson O, Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Ther 2000; 67:478-488.
22. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999; 44:417-421.
23. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602-608.
24. Buffet P, Deray G, Grogl M, Martinez F, Jacobs C. Tolerance and pharmacokinetics of antimony in a patient with renal failure. Nephrol Dial Transplant 1995; 10:1477.
25. Delgado J, Macias J, Pineda JA, Corzo JE, González-Moreno MP, de la Rosa R, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61:766-769.
26. Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, Yifru S, et al. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg 2010; 104:706-712.
27. Hantson P, Luyasu S, Haufroid V, Lambert M. Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy. Pharmacother Sep 2000; 20:1141-1143.
28. Zanoni LZ, Brustoloni YM, Melnikov P, Consolo CE. Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis. Biol Trace Elem Res Dec 2009; 132:35-40.
29. Rodrigues AM, Hueb M, Nery AF, Fontes CJ. Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate. Acta Trop 2007; 102:113-118.
30. Berhe N, Abraham Y, Hailu A, Ali A, Mengistu G, Tsige K, et al. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis. East Afr Med J 2001; 78:608-610.
31. Segura I, Garcia-Bolao I. Meglumine antimoniate, amiodarone and torsades de pointes: A case report. Resuscitation 1999; 42:65-68.
32. Antezana G, Zeballos R, Mendoza C, Lyevre P, Valda L, Cardenas F, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86:31-33.
33. Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367-377.
34. Norvir®(Ritonavir) Tablets UK Summary of Product Characteristics, Abbott Laboratories Ltd, updated 29/4/2010, [Accessed 30 November 2011].
35. Kanyok TP, Killian AD, Rodvold KA, Danziger LH. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob Agents Chemother 1997; 41:982- 986.
36. Tan WW, Chapnick EK, Abter EI, Haddad S, Zimbalist EH, Lutwick LI. Paromomycin-associated pancreatitis in HIVrelated cryptosporidiosis. Ann Pharmacother 1995; 29:22-24.
37. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 2002; 72:505-513.
38. Quinn DI, Day RO. Drug interactions of clinical importance. An updated guide. Drug Saf 1995; 12:393-452.
39. Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J Clin Pharm Ther 2007; 32:585-593.
40. Rees PH, Keating MI, Kager PA, Hockmeyer WT. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980; 2:226-229.
41. Jaser MA, el-Yazigi A, Croft SL. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res 1995; 12:113-116.
42. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4:e628.
43. Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27:1457-1464.
44. McBride MO, Linney M, Davidson RN, Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 1995; 21:710.
45. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113:934-940.
46. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92:561-569.
47. Kuryshev YA, Wang L, Wible BA, Wan X, Ficker E. Antimonybased antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol 2006; 69:1216-1225.
48. Collins JM, Klecker RW Jr, Yarchoan R, Lane HC, Fauci AS, Redfield RR, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986; 26:22-26.
49. World Health Organisation Resources on Neglected Tropical Diseases, World Health Organisation, Geneva, Switzerland. URL: http://www.who.int/neglected- diseases/diseases/en/[Accessed 22 August 2012].
50. Rifadin® (Rifampicin) 300mg capsules UK Summary of product Characteristics, Sanofi aventis, updated 01/11/2011, URL: http://www.medicines. org.uk/EMC/medicine/21223/SPC/Rifadin+300mg+Capsules/#INTERACTIONS [Accessed 23 August 2012].
51. University of Liverpool HIV Drug interactions chart URL: http://www.hiv-druginteractions.org/Interactions.aspx [Accessed 23 August 2012].
52. Perry ST, Buck MD, Shresta S. Better late than never: antivirals for dengue. Expert Rev Anti Infect Ther 2011; 9:755-757.
53. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, et al. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 2011; 85:11183-11195.
54. Hidari KI, Suzuki T. Antiviral agents targeting glycans on dengue virus E-glycoprotein. Expert Rev Anti Infect Ther 2011; 9:983-985.
55. Nitsche C, Behnam MA, Steuer C, Klein CD. Retro peptidehybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res 2012; 94:72-79.
56. Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol 1987; 24:390-392.
57. Azithromycin 250mg film coated tablet UK Summary of Product Characteristics, Sandoz Ltd, updated 12/3/12, URL: http://www.medicines.org.uk/ EMC/medicine/26131/SPC/Azithromycin+250+mg+film-coated+tablet/#tableOfContents [Accessed 23 August 2012].
58. Quality of Evidence and the GRADE System, University of Liverpool HIV Pharmacology Group, URL: http://www.hiv-druginteractions.org/documents/ QualityOfEvidence.pdf [Accessed 3 September 2012].